Modification in media composition to obtain secretory production of STxB-based vaccines using Escherichia coli

Virologica Sinica

Volumn 28, Issue 1, 2013, Pages 43-48

  Sadraeian, Mohammad ^a   Ghoshoon, Mohammad Bagher ^a,b   Mohkam, Milad ^a,b   Karimi, Zeinab ^a,b   Rasoul Amini, Sara ^a,b   Ghasemi, Younes ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Protein vaccine; Soluble expression; STxB; Triton X 100

Indexed keywords

GLYCINE; PROTEIN E7; RECOMBINANT PROTEIN; SHIGA TOXIN; SHIGA TOXIN B SUBUNIT; TRITON X 100; UNCLASSIFIED DRUG; ZINC CHLORIDE;

ARTICLE; CULTURE MEDIUM; DNA MODIFICATION; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI; GENE SEQUENCE; INCUBATION TIME; NUCLEOTIDE SEQUENCE; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN SECRETION; TEMPERATURE SENSITIVITY; VACCINE PRODUCTION;

BACTERIAL SECRETION SYSTEMS; CULTURE MEDIA; ESCHERICHIA COLI; EXTRACELLULAR SPACE; GENE EXPRESSION; PAPILLOMAVIRUS E7 PROTEINS; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; SHIGA TOXINS; VIRAL VACCINES;

ESCHERICHIA COLI; SHIGELLA DYSENTERIAE;

EID: 84873441577     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-013-3286-9     Document Type: Article

References (26)

1. Baneyx F and Mujacic M. 2004. Recombinant protein folding and misfolding in Escherichia coli. Nat Biotechnol, 22: 1399-1408.
2. Buchner J, Pastan I and Brinkmann U. 1992. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem, 205: 263-270.
3. Choi J H and Lee S Y. 2004. Secretory and extracellular production of recombinant proteins using Escherichia coli. Appl Microbiol Biotechnol, 64: 625-635.
4. Choi N W, Estes M K and Langridge W H R. 2005. Oral immunization with a shiga toxin B subunit: Rotavirus NSP4(90) fusion protein protects mice against gastroenteritis. Vaccine, 23: 5168-5176.
5. Goncalves A N, Meschiari C A, Stetler-Stevenson W G, Nonato M C, Alves C P, Espreafico E M and Gerlach R F. 2012. Expression of soluble and functional full-length human Matrix Metalloproteinase-2 in Escherichia coli. J Biotechnol 157: 20-24.
6. Haicheur N, Bismuth E, Bosset S, Adotevi O, Warnier G, Lacabanne V, Regnault A, Desaymard C, Amigorena S and Ricciardi-Castagnoli P. 2000. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J Immunol, 165: 3301-3309.
7. Haicheur N, Benchetrit F, Amessou M, Leclerc C, Falguires T, Fayolle C, Bismuth E, Fridman W H, Johannes L and Tartour E. 2003. The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1 dominant polarization. Int immunol, 15: 1161-1171.
8. Han L, Doverskog M, Enfors S O and Häggström L. 2002. Effect of glycine on the cell yield and growth rate of Escherichia coli: evidence for cell-density-dependent glycine degradation as determined by 13C NMR spectroscopy. J Biotechnol, 92: 237-249.
9. Humphreys D P, Sehdev M, Chapman A P, Ganesh R, Smith B J, King L M, Glover D J, Reeks D G and Stephens P E. 2000. High-level periplasmic expression in Escherichia coli using a eukaryotic signal peptide: importance of codon usage at the 5′end of the coding sequence. Protein Expr Purif, 20: 252-264.
10. Janssen K P, Vignjevic D, Boisgard R, Falguires T, Bousquet G, Decaudin D, Dolli F, Louvard D, Tavitian B and Robine S. 2006. In vivo tumor targeting using a novel intestinal pathogen-based delivery approach. Cancer Res, 66: 7230-7237.
11. LaCasse E C, Saleh M T, Patterson B, Minden M D and Gariepy J. 1996. Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice. Blood, 88: 1561-1567.
12. Lee R S, Tartour E, Van der Bruggen P, Vantomme V, Joyeux I, Goud B, Fridman W H and Johannes L. 1998. Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. Eur J Immunol, 28: 2726-2737.
13. Li J, Liu J, Lan X, Cheng J, Wu R, Lou Z Z, Yin X, Li X, Li B and Yang B. 2009. Cloning the structure genes and expression the N gene of porcine epidemic diarrhea virus DX. Virol Sin, 24: 179-186.
14. Li Y L, Liu J, Liu J N and Zhang J. 2011. Immunization of protein HPV16 E7 in fusion with mouse HSP70 inhibits the growth of TC-1 cells in tumor bearing mice. Vaccine, 29: 5959-5962.
15. Nakagawa I, Nakata M, Kawabata S and Hamada S. 1999. Regulated expression of the Shiga toxin B gene induces apoptosis in mammalian fibroblastic cells. Mol Microbiol, 33: 1190-1199.
16. Ni Y and Chen R. 2009. Extracellular recombinant protein production from Escherichia coli. Biotechnol Lett, 31: 1661-1670.
17. O'Brien A D, Tesh V L, Donohue-Rolfe A, Jackson M P, Olsnes S, Sandvig K, Lindberg A A and Keusch G T. 1992. Shiga toxin: biochemistry, genetics, mode of action and role in pathogenesis. Curr Top Microbiol Immunol, 180: 65-94.
18. Ohmura M, Yamamoto M, Tomiyama-Miyaji C, Yuki Y, Takeda Y and Kiyono H. 2005. Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation. Infect Immu, 73: 4088-4097.
19. Sadraeian M, Honari H, Madanchi H and Hesaraki M. 2011. Cloning and Expression of CtxB-StxB in Esherichia coli: A challenge for Improvement of Immune Response Against StxB. Iran J Pharm Sci, 7: 185-190.
20. Sedighzadeh S S, Shamsara M and Shahpiri A. 2012. Fusion Protein Strategy to Increase Expression and Solubility of Hypervariable Region of VP2 Protein of Infectious Bursal Disease Virus in Escherichia coli. Prot J: 1-5.
21. Shaw C A and Starnbach M N. 2003. Using modified bacterial toxins to deliver vaccine antigens. ASM News, 69: 384-389.
22. Vingert B, Adotevi O, Patin D, Jung S, Shrikant P, Freyburger L, Eppolito C, Sapoznikov A, Amessou M and Quintin-Colonna F. 2006. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol, 36: 1124-1135.
23. Wang P, Song P, Li X, Su R R, Wang H and Zhu G P. 2012. Study on soluble expression of glutamate dehydrogenase from tea plant in Escherichia coli using fusion tags. African J Biotechnol, 11: 6241-6250.
24. Weikert C, Sauer U and Bailey J E. 1998. An Escherichia coli host strain useful for efficient overproduction of secreted recombinant protein. Biotechnol Bioeng 59: 386-391.
25. Yang J, Moyana T, MacKenzie S, Xia Q and Xiang J. 1998. One Hundred Seventy-Fold Increase in Excretion of an FV Fragment-Tumor Necrosis Factor Alpha Fusion Protein (sFV/TNF-α) from Escherichia coli Caused by the Synergistic Effects of Glycine and Triton X-100. Appl Environ Microbiol, 64: 2869-2874.
26. Zhang S, Fan R, Yang T, Sun Y, Li J, Xu Q and Zhou P. 2009. An improved strategy for efficient expression and purification of soluble HIV-1 tat protein in E. coli. Virol Sin, 24: 518-528.